[When is it worth reducing overuse of health care services? The example of prescribing expensive antihypertensives].
Gandjour A, Lauterbach KW.
Med Klin (Munich). 2005 Sep 15. 100(9):535-41. PMID: 16170641
Adjunct Professor of Health Policy and Management
Health Policy and Management
Gandjour A, Lauterbach KW.
Med Klin (Munich). 2005 Sep 15. 100(9):535-41. PMID: 16170641
Gandjour A, Lauterbach KW.
Med Decis Making. 2005 May-Jun. 25(3):341-7. PMID: 15951461
Gandjour A, Lauterbach KW.
J Health Econ. 2005 Jul. 24(4):715-24. PMID: 15960993
Gandjour A, Kerschbaum T, Reis A, Lauterbach KW.
Int J Technol Assess Health Care. 2005. 21(3):319-25. PMID: 16110711
Gandjour A, Lauterbach KW.
Psychiatr Prax. 2004 Apr. 31(3):157-62. PMID: 15042479
Gandjour A, Lauterbach KW.
Med Decis Making. 2003 Nov-Dec. 23(6):518-25. PMID: 14672112
Gandjour A, Neumann I, Lauterbach KW.
Eur J Cardiothorac Surg. 2003 Oct. 24(4):571-7; discussion 577-8. PMID: 14500076
Gandjour A, Lauterbach KW.
Health Care Anal. 2003 Sep. 11(3):229-44. PMID: 14708935
Gandjour A, Lauterbach KW.
J Nephrol. 2003 Jul-Aug. 16(4):500-10. PMID: 14696751
Gandjour A, Lauterbach KW.
J Eval Clin Pract. 2003 May. 9(2):161-9. PMID: 12787179
Karl Lauterbach, an adjunct faculty member and alumnus of Harvard T.H. Chan School of Public Health, was sworn in as Germany’s health minister on December 8, 2021.
A five-year-old drug price regulatory system in Germany may be a good model for the U.S. to consider to tackle its own problem with unaffordable prescription drug prices, according to experts from Harvard T.H. Chan School of Public…